SKYE Relative Valuation - Skye Bioscience Inc - Alpha Spread

Skye Bioscience Inc
NASDAQ:SKYE

Watchlist Manager
Skye Bioscience Inc Logo
Skye Bioscience Inc
NASDAQ:SKYE
Watchlist
Price: 5.49 USD 4.77% Market Closed
Market Cap: 154.1m USD
Have any thoughts about
Skye Bioscience Inc?
Write Note

Relative Value

There is not enough data to reliably calculate the relative value of SKYE.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SKYE Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.7
vs History
vs Industry
Median 3Y
-1.8
Median 5Y
-2.3
Industry
23.9
Forward
-5.2
vs History
vs Industry
Median 3Y
-2.5
Median 5Y
-2.9
Industry
22.2
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-2.3
Industry
24
vs History
52
vs Industry
Median 3Y
2.3
Median 5Y
2.4
Industry
2.5
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.4
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.5
vs History
vs Industry
Median 3Y
-1.6
Median 5Y
-1.9
Industry
5.1
vs History
vs Industry
Median 3Y
-1.5
Median 5Y
-1.9
Industry
4.7
Forward
-3.1
vs History
vs Industry
Median 3Y
-1.9
Median 5Y
-2.6
Industry
6.6
vs History
vs Industry
Median 3Y
-1.9
Median 5Y
-2.6
Industry
4.7
vs History
47
vs Industry
Median 3Y
15.6
Median 5Y
5.6
Industry
4.7

Multiples Across Competitors

SKYE Competitors Multiples
Skye Bioscience Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Skye Bioscience Inc
NASDAQ:SKYE
154.1m USD 0 -3.6 -1.9 -1.9
US
Abbvie Inc
NYSE:ABBV
341.9B USD 6.2 64.6 15.8 24.1
US
Amgen Inc
NASDAQ:AMGN
180.5B USD 5.8 57.7 20.2 36.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
129B USD 9.6 29.8 26.2 29
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.6B USD 12 -252.2 26.8 28.2
US
Gilead Sciences Inc
NASDAQ:GILD
104.5B USD 3.8 99.3 9.4 12
US
Epizyme Inc
F:EPE
94.1B EUR 1 981.8 -505.7 -550.7 -536
AU
CSL Ltd
ASX:CSL
142.3B AUD 6.5 36.7 22.4 28
US
Seagen Inc
F:SGT
39.3B EUR 19.1 -58.5 -63 -56.9
US
Palatin Technologies Inc
LSE:0KF3
38.5B USD 6 513.5 -1 169.6 -1 185.3 -1 173.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
35.4B USD 15.1 -485.3 213.7 328.9
P/E Multiple
Earnings Growth
US
Skye Bioscience Inc
NASDAQ:SKYE
Average P/E: 57.6
Negative Multiple: -3.6
N/A
US
Abbvie Inc
NYSE:ABBV
64.6
406%
US
Amgen Inc
NASDAQ:AMGN
57.7
74%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29.8
56%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -252.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
99.3
71%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -505.7 N/A
AU
CSL Ltd
ASX:CSL
36.7
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.5 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 169.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -485.3 N/A
EV/EBITDA Multiple
EBITDA Growth
US
Skye Bioscience Inc
NASDAQ:SKYE
Average EV/EBITDA: 47.8
Negative Multiple: -1.9
N/A
US
Abbvie Inc
NYSE:ABBV
15.8
28%
US
Amgen Inc
NASDAQ:AMGN
20.2
57%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
26.2
47%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
39%
US
Gilead Sciences Inc
NASDAQ:GILD
9.4
10%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -550.7 N/A
AU
CSL Ltd
ASX:CSL
22.4
45%
US
S
Seagen Inc
F:SGT
Negative Multiple: -63 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 185.3 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
213.7
N/A
EV/EBIT Multiple
EBIT Growth
US
Skye Bioscience Inc
NASDAQ:SKYE
Average EV/EBIT: 69.5
Negative Multiple: -1.9
N/A
US
Abbvie Inc
NYSE:ABBV
24.1
86%
US
Amgen Inc
NASDAQ:AMGN
36.6
95%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29
49%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
12
26%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -536 N/A
AU
CSL Ltd
ASX:CSL
28
59%
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.9 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 173.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
328.9
N/A

See Also

Discover More
Back to Top